PT-141 – Forschung

Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.

Spielmans GI · J Sex Res (2021)

Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.

Weinberger JM, Houman J, Caron AT, Patel DN, Baskin AS, Ackerman AL · Obstet Gynecol (2018)

Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.

Toledo RG, Winkelman WD, Reyes-Gonzalez D, Bergeron S, Fladger A, Hacker MR · J Minim Invasive Gynecol (2026)

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.

Mayer D, Lynch SE · Ann Pharmacother (2020)

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.

Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R · Obstet Gynecol (2019)

Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.

White WB, Myers MG, Jordan R, Lucas J · J Hypertens (2017)

Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I · Womens Health (Lond) (2016)

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

Diamond LE, Earle DC, Garcia WD, Spana C · Urology (2005)

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY · J Urol (2008)

Safety Profile of Bremelanotide Across the Clinical Development Program.

Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R · J Womens Health (Larchmt) (2022)

RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.

Safarinejad MR · J Sex Med (2008)

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R · J Sex Med (2006)

Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.

Clayton AH, Lucas J, DeRogatis LR, Jordan R · Clin Ther (2017)

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB · Int J Impot Res (2004)

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.

Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB · Int J Impot Res (2004)

The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.

Koochaki P, Revicki D, Wilson H, Pokrzywinski R, Jordan R, Lucas J · J Womens Health (Larchmt) (2021)

Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.

Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A · J Womens Health (Larchmt) (2022)

Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J · J Sex Med (2019)

Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov

Einfach gesagt: Further research with standardized methodologies and comprehensive reporting is needed to strengthen the evidence base.

Ashour AM. · Frontiers in medicine (2026)

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Einfach gesagt: While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.

Mavrych V, Shypilova I, Bolgova O. · Frontiers in aging (2026)